Table 2. Risk factors for 30-day mortality among 16 patients infected with tigecycline- and carbapenem-resistant Klebsiella pneumoniae.
| Variables | 30-Day Survivor (n = 9) | 30-Day Non-survivor (n = 7) | p value |
|---|---|---|---|
| Age (years; mean ± SD) | 66.1 ± 19.1 | 62.6 ± 34.6 | 0.452 |
| Sex | 0.286 | ||
| Female | 5 | 2 | |
| Male | 4 | 5 | |
| Underlying disease | |||
| DM | 5 | 5 | 0.633 |
| CVA | 3 | 1 | 0.585 |
| Solid tumor | 4 | 2 | 0.633 |
| Hematological malignancy | 0 | 1 | 0.438 |
| Uremia | 2 | 0 | 0.475 |
| Liver cirrhosis | 1 | 0 | 1.000 |
| Type of infection | 0.035 | ||
| UTI | 8 | 2 | |
| High-risk infection sitea (Non-UTI) | 1 | 5 | |
| APACHE II (mean ± SD) | 21.56 ± 10.33 | 24.29 ± 7.46 | 0.289 |
| Prior tigecycline treatment | 3 | 1 | 0.585 |
| Appropriate antibiotics treatment | 0.549 | ||
| Yes | 6 | 4 | |
| No | 3 | 3 | |
| MICs | |||
| Meropenem MIC > 4 mg/L | 1 | 3 | 0.262 |
| Tigecycline MIC > 4 mg/L | 7 | 3 | 0.302 |
APACHE II, Acute Physiology and Chronic Health Evaluation II, BTI, biliary tract infection; CVA, cerebrovascular accident; DM, diabetes mellitus; MIC, minimal inhibitory concentration; SD, standard deviation; UTI, urinary tract infection.
a High-risk infection types: any infection except urinary tract infection.